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Abstract
Introduction: Deposition of abnormally phosphorylated tau (phospho-tau) occurs in Alzheimer’sdisease but also
with brain ageing. The Braak staging scheme focused on neurofibrillary tangles, butabundant p-tau is also present
in neuropil threads, and a recent scheme has been proposed by theBrainNet Europe consortium for staging tau
pathology based on neuropil threads. We determined therelationship of threads to tangles, and the value of
staging for threads in an unselected population-representative ageing brain cohort. We also determined the
prevalence of astroglial tau pathologies, and their relationship to neuronal tau. Phospho-tau pathology was
determined by immunohistochemistry (AT8 antibody) in the MRC-CFAS neuropathology cohort. Neuropil threads
were staged using the BrainNet Europe protocol for tau pathology, and compared with Braak tangle stages.
Astroglial tau pathology was assessed in neo-cortical, mesial temporal and subcortical areas.
Results: Cases conformed well to the hierarchical neuropil threads staging of the BrainNet Europe protocol and
correlated strongly with Braak staging (r=0.84, p < 0.001). Based on the areas under the receiver operator curves
(AUC), incorporating either threads or tangle staging significantly improved dementia case identification to a similar
degree over age alone (Braak stage X2(1)=10.1, p=0.002; BNE stage X2(1)=9.7, p=0.002). Thorn-shaped astrocytes,
present in 40 % of cases, were most common in mesial temporal lobe, then brainstem, and were associated with
subpial tau-positive neurites (mesial temporal: X2(1)=61.3, p < 0.001; brainstem: X2(1)=47.9, p < 0.001). Adding thorn
astrocytes did not improve dementia prediction (AUC: X2(1)=0.77, p=0.381), but there was a weak relationship
between numbers of areas involved and staging for threads or tangles (r=0.17, p=0.023). Neuropil threads develop
hierarchically in parallel with neurofibrillary tangles.
Conclusions: The BrainNet Europe staging protocol is straightforward to apply, and offers similar predictive value
for dementia to Braak tangle staging. Astroglial tauopathy, particularly thorn shaped astrocyte formation, does not
relate to dementia status, but the association with phospho-tau neurites may suggest a pathogenic relationship to
neuronal tau pathology.
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Introduction
Deposition of abnormal forms of the microtubule-
associated protein tau, including phosphorylated forms (p-
tau), occurs in a variety of inclusions in neurones and glia,
and is of diagnostic utility, in a subset of neurodegenera-
tive disorders referred to collectively as the tauopathies
[15]. In Alzheimer’s disease (AD), deposition as neurofib-
rillary tangles (NFTs), pre-tangles, neuropil threads (NTs),
dystrophic neurites in neuritic plaques, and granulovacuo-
lar degeneration, is associated with βA4-amyloid depos-
ition. Identification of mutations of the MAPT gene,
which encodes tau, in a subset of the frontotemporal lobar
degenerations (FTLD-TAU) confirmed the molecular
pathogenicity of abnormal tau proteins [9].
However, p-tau deposition is also common in the ageing
brain, particularly as AD-type neuropathological lesions,
along with AD-type deposits of β-amyloid. Studies in the
population-representative Medical Research Council
Cognitive Function and Ageing Study have shown overlap
in burden of AD pathology in the brains of older people
with and without dementia at death, such that thresholds
for the prediction and diagnosis of dementia cannot be de-
fined [22, 25]. This is supported by findings in other large
unselected or community-based autopsy series showing
AD-type lesions in non-demented individuals [3, 10, 12,
14, 18]. The overlap increases in the oldest old such that
the relationship of plaques and NFTs to dementia be-
comes increasingly attenuated [11, 27, 28]. Conversely, a
subset of elderly individuals who have only minimal AD
pathology are demented, suggesting a role for other fac-
tors, such as oxidative damage [31]. This corresponds to
cases reported in other series that have an AD-like clinical
presentation but with insufficient neuropathology to ex-
plain dementia [30]. Neurofibrillary tangle stage is a better
correlate with dementia than plaques, but these findings
suggest a need to find other drivers of cell dysfunction in
the ageing brain and also to better define AD type path-
ologies at cellular and molecular levels.
NFT pathology in AD, and ageing, progresses in a ste-
reotyped, hierarchical manner and therefore can be
staged using the 6-tiered scheme devised by Braak [5].
NFTs may be assessed using either silver impregnation
or by immunohistochemistry to abnormally phosphory-
lated tau protein [4], the latter providing more uniformity
in detection and assessment [2]. Much of the tau path-
ology, however, lies within neuritic processes as neuropil
threads. Recently a 6-stage scheme based on the assess-
ment of NTs was devised by the BrainNet Europe consor-
tium [1]. NT pathology progresses anatomically in a
similar hierarchy to tangles.
Given the abundance of tau pathology within the neur-
itic compartment, it is possible that this form of tau
pathology has an important influence on cognition. We
therefore evaluated the BrainNet Europe neuropil thread
staging scheme (BNE NT staging) in the CFAS ageing
brain cohort, compared this with Braak NFT staging and
assessed the relationship of NTs to dementia. The
population-based and unselected nature of the CFAS co-
hort is well-suited to this study because the cohort al-
lows assessments of the relationships between pathology
and dementia in an unbiased way, without the ceiling-
floor effects and other biases inherent in case—control
cohorts pre-selected by clinical presentation [36]. In
addition we examined other age-related forms of p-tau
pathology, particularly astroglial tau, with a view to
obtaining better prevalence data for age-related tau
pathology and evaluating the relationship of these less
investigated pathologies to cognition.
Materials and methods
Tissue was obtained from the neuropathology cohort of
the MRC-CFAS [reviewed in [36]] following Research
Ethics Committee approval. Two entire sub-cohorts were
used to maintain the unbiased population-representative
base of the study (Cambridge and Newcastle), totalling
183 cases Neuropathological lesions were previously
assessed in this cohort, including AD-neuropathology
using the CERAD protocol [23] and Braak NFT stage,
based on immunohistochemistry and silver staining. De-
mentia status at death was based on all information avail-
able for each study participant, including algorithmic
assessment in life (AGECAT), information from death cer-
tification and a Retrospective Informant Interview (RINI)
developed by CFAS [20, 24].
NTs were staged using the BNE NT staging protocol
[1] in sections immunostained for p-tau using the AT8
antibody, which is commonly used in diagnostic practice
and identifies tau phosphorylated at serine 202/threo-
nine 205. Sections from tissue blocks of the following
areas were stained: temporal cortex (Brodmann Area 21/
22); occipital cortex (BA17/18); posterior hippocampus
and adjacent mesial temporal structures; anterior hippo-
campus and adjacent mesial temporal structures (where
available); midbrain; pons; striatum. Briefly, for BNE NT
stage, threads were semi–quantified as 0, +, ++ or +++,
in comparison with the published reference images, in
transentorhinal cortex, entorhinal cortex, occipitotem-
poral gyus, lateral temporal cortex (BA22/21), occipital
association cortex (BA18) and primary visual cortex
(BA17) entorhinal and transentorhinal cortex, allowing
distinction of 6 stages based on the progressive recruit-
ment of these anatomical areas by neuropil threads of ++
of +++ intensity. The presence of tau-positive neurons
(tangles and pre-tangles) was also noted.
In addition to this BrainNet protocol, NTs and NFTs
were also noted in subcortical structures (midbrain, pons
and striatum). Additional cytopathologies were also
noted in all of these cortical and subcortical areas,
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namely astroglial tau pathologies, particularly thorn-
shaped astrocytes (TSA), subpial tau in neuritic process
at the brain surface, brainstem subependymal tau pro-
cesses, argyrophilic grains.
Immunohistochemisty was performed using a standard
avidin biotin method combined with diaminobenzidine
(Vector Laboratories, Peterborough, UK). Haematoxylin
and eosin was used as a counterstain. Phosphorylated
tau was detected using the AT8 antibody (1:400, micro-
wave antigen retrieval for 10 mins in trisodium citrate).
Statistical analysis
Means (standard deviations) are reported. Differences
between means were tested using Student t test (t) for
independent samples. The chi-square test (X2) was used
for comparison of categorical data. Spearman coefficient
was calculated to verify the correlation between Braak
NFT stage, BNE NT stage and TSA. To verify the influ-
ence of age on Braak NFT stage, BNE NT stage and TSA
ordinal logistic regression was used with BNE NT stage,
Braak NFT stage and TSA as dependent variables and
age as independent variable, whereas the relationship of
age, Braak NFT stage, BNE NT stage and TSA with de-
mentia was tested using logistic regression with demen-
tia status as dependent variable. Receive operator curve
(ROC) regression analyses were performed to verify that
adding Braak NFT stage, BNE NT stage or TSA would
better discriminate between dementia status than when
only age was considered in the model. The chi-square
test (X2) for the equality of areas under the ROC curves
(AUC) was used. All tests were 2-tailed. Statistical ana-
lyses were performed using statistical package STATA,
version 12.
Results
In total, 183 brains were included in the sample. Among
them, 112 (61 %) were women. Mean age of death was
85.9(7.7) years. Dementia at death was present in 106
(58 %) of cases, 69(38 %) did not have dementia and de-
mentia status at death was could not be determined in
8(4 %) participants.
Neuropil threads
Cases conformed well to the hierarchical sequence of
anatomical involvement implicit in the BrainNet Europe
and Braak staging protocols, with only two cases (1.1 %)
showing minor deviation. One case showed ++ neuropil
thread staining in the occipital region, but only + in tem-
poral, thus bypassing this area in terms of stage progres-
sion. A second case showed a focus of ++ staining in
BA18 (which would correspond to Braak stage V), but
otherwise was typically grade II, which was the grade
assigned. A third case showed a slightly unusual
pericapillary granular tau reactivity, but this was not
neuritic and did not affect staging.
Other Age-related Tau pathologies
Tau pathology in astrocytes was of varying morphology
and was common in the cohort (Fig. 1). TSA were com-
mon in subpial or subependymal regions (40 % in any
area examined) (Fig. 2). They were present in one of
these regions in 27 % of cases, in two regions in 10 %
and in three regions in 2 % and were most frequent in
the order mesial temporal region, brainstem (midbrain
or pons), cortical regions. They were also observed in
cortical white matter in two cases. Tau-positive astro-
cytes in grey matter were TSA or tufted astrocytes, or
astrocytes with a similar morphology, varying from
ramified profiles to astrocytes with finely granular tau-
immunoreactive processes [15]. Tufted astrocytes (in-
cluding those with finely granular processes) were ob-
served in 18 cases (10 %) and could be seen in cortical,
mesial temporal or subcortical grey matter, usually as
isolated or sparse positive cells. There were significantly
more areas with TSA in brains with tufted astrocytes
than in those without [0.95(0.22) vs 0.50(0.06), t(181) =
−2.45, 95 % CI(mean difference) = 0.39; 0.61, p = 0.016].
Tau-positive neuritic processes were observed in the
immediate subpial area, often associated with corpora
amylacea and TSA, and also in subependymal areas,
or even within the ependyma (Fig. 1). Subpial neuritic
processes showed significant associations with TSA in
the mesial temporal [X2(1) = 61.3, p < 0.001) and
brainstem (X2(1) = 47.9, p < 0.001] areas. Subpial neur-
ites were observed in the mesial temporal region in
68 (37 %) of cases and in the brainstem regions in 60
(32 %) of cases. Argyrophilic grains, identified on tau
immunohistochemistry, were observed in 9 (5 %) of
cases.
Relationship between BNE NT stage, and Braak NFT stage,
and TSA
There was a strong correlation between BNE NT stage
(BrainNet Europe) and Braak NFT stage [r = 0.84, p < 0.001,
Table 1]. There were weak correlations between TSA and
Braak NFT stage [r = 0.17, p = 0.023, Table 2] and between
TSA and BNE NT stage [r = 0.17, p = 0.023, Table 3]; the
identical correlation values here reflects the similarity in
BNE NT stage and Braak NFT stage and the use of a non-
parametric test.
Relationship between BNE NT stage, braak NFT stage and
TSA with age according to dementia status
For the further analyses presented, Braak NFT stage was
grouped as 0/II, III/IV V/BNE NT stage as I/II, III/IV V/
VI and TSA as none, 1 area and 2/3 areas. Their distri-
bution according to dementia status is shown in Table 4.
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The relationships between Braak NFT stage, BNE NT
stage and TSA with age, according to dementia status,
were verified using ordinal logistic regression with BNE
NT stage, Braak NFT stage and TSA stage as dependent
variables and age as independent variable (Table 5). The
relationships between BNE NT stage, Braak NFT stage
with age were significant only among participants with-
out dementia. The relationship between TSA and age
was not significant in either group, but TSA did show a
trend to increase with age among participants with
Fig. 1 Examples of tau pathologies in the cohort. a. Subpial TSA temporal cortex. Note layer of subpial tau + neurites (arrow). b. Subependymal
TSA hippocampal region. c. Midbrain subpial TSA and neurites. d. TSA in CA2 region of hippocampus. e. Astrocyte with finely tau immunoreactive
processes in striatum and, f. in temporal cortex. g. Tau + neurites pons, without TSA. h. Tau positive neurites in subependymal and ependymal
(arrow and inset) location associated with TSA, hippocampal region
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dementia, and also when the demented and non-
demented groups were considered together, though this
was marginal with a low odds ratio [OR 1.06; 95 % CI
(OR) 1.02;1.11, p = 0.003].
Risk prediction of dementia based on age, BNE NT stage,
braak NFT stage and TSA
To verify the added value of investigating Braak NFT
stage, BNE NT stage and TSA on age in terms of
dementia risk prediction we compared a logistic re-
gression model where age was the only predictor of
dementia with models where Braak NFT stage, BNE
NT stage and TSA were added with age as independ-
ent variables (Table 6). We verified the difference in
models by testing the equality of areas under the
ROC curves (AUC) based on the predicted values cof-
fered by those models. The AUC in the models that
had age and Braak NFT stage [X2(1) = 10.1, p = 0.002)
Fig. 2 a. Frequencies of glial and subpial neuritic tau pathologies. b. Distribution of number of areas involved by TSA. c. Venn diagram showing
the distribution of areas affected with TSA
Table 1 Distribution of BNE NT stage and braak NFT stage
Braak NFT
stage
BNE NT stage n(cell %)
I II III IV V VI
0 5(2.7) 0(0.0) 0(0.0) 0(0.0) 0(0.0) 0(0.0)
I 9(4.9) 3(1.6) 0(0.0) 0(0.0) 0(0.0) 0(0.0)
II 20(10.9) 18(9.8) 8(4.4) 1(0.6) 0(0.0) 0(0.0)
III 3(1.6) 18(9.8) 11(6.0) 2(1.1) 1(0.6) 1(0.6)
IV 0(0.0) 3(1.6) 26(14.2) 14(7.7) 3(1.6) 0(0.0)
V 0(0.0) 0(0.0) 2(1.1) 7(3.8) 6(3.3) 7(3.8)
VI 0(0.0) 0(0.0) 0(0.0) 1(0.6) 3(1.6) 11(6.0)




None 1 area 2 areas 3 areas
0 5(2.7) 0(0.0) 0(0.0) 0(0.0)
I 11(6.0) 1(0.6) 0(0.0) 0(0.0)
II 30(16.4) 13(7.1) 4(2.2) 0(0.0)
III 21(11.5) 10(5.5) 3(1.6) 2(1.1)
IV 21(11.5) 16(8.7) 8(4.4) 1(0.6)
V 10(5.5) 8(4.4) 4(2.2) 0(0.0)
VI 12(6.6) 2(1.1) 0(0.0) 1(0.6)
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or BNE NT stage (X2(1) = 9.7, p = 0.002] were predic-
tors was significantly larger (12 and 11 % larger re-
spectively) than the model that just had age as a
predictor. However, adding TSA to age did not sig-
nificantly increase the AUC [X2(1) = 0.77, p = 0.381].
There was no significant difference between the
model that included Braak NFT stage with the model
that included BNE NT stage in terms of prediction of
dementia [X2(1) = 0.15, p = 0.699] (Table 6).
Discussion and conclusions
Tau pathology associated with brain ageing appears to
form a continuum with that associated with AD. There
is a hierarchy of progression that differs from that of
amyloid deposition, as defined in staging schemes such
as that of Thal et al. [34]. Indeed, NFT formation may
precede Aβ-amyloid deposition, with occasional NFTs
appearing at quite young ages [6]. Tau aggregation in
mesial temporal structures without significant Aβ en-
countered in older brains has given rise to the term “pri-
mary age-related tauopathy” (PART) [7], but this may
reflect early tau deposition preceding Aβ-stages, and
thus be part of the ageing-AD spectrum [8]. The lack of
a discontinuity between age-related tauopathy and the
tauopathy described in AD is consistent with subclinical
tau and amyloid representing early stages of AD, with
increasing likelihood of dementia with increasing bur-
dens of pathology. It is therefore important to under-
stand the different forms of tau pathology in brain
ageing, their pathogenesis and relationship to dementia.
Much of the work on tau pathology and pathogenesis
has focused on the neurofibrillary tangle, located within
the neuronal soma. However, the NFT pathology seen in
AD, some tauopathies, and ageing is accompanied by
tau pathology within the neuritic compartment in the
form of NTs. Given that tau modification affects its abil-
ity to regulate microtubule function [26], neuritic-
compartment tau pathology may be an important
contributor to dysfunction of axons and dendrites, and
failure of synaptic support. The contribution of neuritic
tauopathy to cognitive function is therefore an important
question. The strong correlation observed in this
population-representative cohort between BNE NT stage
and Braak NFT stage suggests that NT formation in gen-
eral parallels that of NFT formation, and supports the
objective of the BrainNet Europe approach to the simpli-
fication of the staging process. The fact that both NTs
and NFTs are so overlapped may suggest that their




None 1 area 2 areas 3 areas
I 32(17.5) 4(2.2) 1(0.6) 0(0.0)
II 24(13.1) 12(6.6) 5(2.7) 1(0.6)
III 20(10.9) 19(10.4) 7(3.8) 1(0.6)
IV 15(8.2) 6(3.3) 3(1.6) 1(0.6)
V 7(3.8) 4(2.2) 2(1.1) 0(0.0)
VI 12(6.6) 5(2.7) 1(0.6) 1(0.6)
Table 4 Distribution of Braak NFT stage, BNE NT stage and TSA
according to dementia status
No dementia Dementia Unknown
Braak NFT Stage
0/II 36(56.3) 23(35.9) 5(7.8)
III/IV 31(37.8) 48(58.5) 3(3.7)
V/VI 2(5.4) 35(94.6) 0(0.0)
BNE NT Stage
I/II 43(54.4) 32(40.5) 4(5.1)
III/IV 24(33.3) 44(61.1) 4(5.6)
V/VI 2(6.3) 30(93.8) 0(0.0)
TSA
None 16(32.0) 31(62.0) 3(6.0)
1 area 4(17.4) 19(82.6) 0(0.0)
2/3 areas 49(44.6) 56(50.9) 5(4.6)
Table 5 Ordinal logistic regression analyses investigating
relationships of Braak NFT stage, BNE NT stage and TSA with
age according to dementia status
Dependent No dementia Dementia
variables OR 95 % CI(OR) p OR 95 % CI(OR) p
Braak NFT St. 1.08a (1.01; 1.15) 0.017 0.99 (0.94; 1.04) 0.674
BNE NT St. 1.09a (1.02; 1.16) 0.014 0.98 (0.93; 1.03) 0.473
TSA 1.02 (0.96; 1.09) 0.504 1.06 (1.00; 1.12) 0.072
aExplanatory note: OR here means that that for each extra year of life: the
chances of moving from braak 0/II to III/IV (or braak III/IV to V/VI) increases in
1.08 times and the chances of moving from NTS I/II to III/IV (or NTS III/IV to V/
VI) increases in 1.09 times
Table 6 Logistic regression analyses investigating relationships
between NTS, braak NFTS and TSA
OR 95 % CI(OR) p AUC 95 % CI(AUC)
Age, years 1.11 (1.06; 1.17) <0.001 0.71 (0.63; 0.79)
Braak NFT Sta 0.80 (0.73; 0.86)
III/IV 1.60 (0.75; 3.42) 0.226
V/VI 23.01 (4.90; 108.00) <0.001
BNE NT Stb 0.79 (0.72; 0.86)
III/IV 1.90 (0.92; 3.92) 0.082
V/VI 17.43 (3.78; 80.26) <0.001
TSAc 0.72 (0.64; 0.80)
2 areas 1.47 (0.69; 3.13) 0.313
2/3 areas 3.03 (0.91; 10.08) 0.070
aReference: Braak NFT Stage 0-II. bReference: BNE NT Stage I/II. cReference TSA
0/1 area
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development is synchronous, but our data, which is
cross-sectional, do not allow us to determine this defini-
tively. The relationship of tau to dementia is thus to
neuronal tau in general, not specifically to either NFTs
or NTs. It would be further of interest to determine if
NTs and NFTs are occurring within the same popula-
tions of neurones. Like NFT staging, we found that NT
progression is highly stereotypic so that only ~1 % of
cases deviated from the BNE NT staging scheme, and
this was due to isolated foci of neocortical NT forma-
tion. The BNE NT staging scheme therefore appears to
be reliable and relatively easy to apply.
BNE NT stage and Braak NFT stage both increase with
age among the participants without dementia, consistent
with the known age effects on prevalence of tau path-
ology over the age-course [6], but this age-effect was not
seen within the individuals who had dementia, who had
a tendency to be at the higher stages. This age-effect in
non-demented individuals was not seen with TSA.
Using a logistic regression model, inclusion of BNE
NT stage adds additional information about the demen-
tia status compared with age alone. Although BNE NT
stage assigns some cases to a different stage compared
with Braak NFT protocol (Table 1), both schemes have a
similar effect in dementia models, so that the addition of
BNE NT stage does not provide additional information
beyond Braak NFT staging. A common assumption in
dementia neuropathology regards Braak NFT stages V
and VI as being highly predictive of dementia. Compari-
son of NT and NFT stages show that 10 cases with Braak
NFT stages V or VI have a BNE NT stage of IV or less,
similarly 5 cases of NT stage V or VI were scored Braak
NFT stage IV or less. For either protocol a score of
stages V or VI is highly predictive of dementia; only 1 in
20 cases for either protocol would be incorrectly
assigned to a dementia diagnosis on this metric. How-
ever, as previously reported in the CFAS cohort, between
1 in 3 (BrainNet Europe) and 1 in 4 (Braak) elderly indi-
viduals with stage 0-II tauopathy have dementia at death,
and approximately 60 % have dementia with stage III-IV
pathology using either protocol [22, 25]. Thus, as with
NFTs, there is considerable overlap in burdens of NT
pathology between those with dementia and those with-
out in this population sample.
A spectrum of astroglial tau-pathology is increasingly
recognised as a common feature in brain ageing, distinct
from the forms of astrocytic tau, such as astrocytic pla-
ques, tufted astrocytes and globular inclusions that have
diagnostic significance for specific tauopathies [15].
There has been limited evaluation of these forms of age-
related astroglial tau and a recent consensus paper has
suggested a more harmonised approach to its assess-
ment under the umbrella term of ageing-related tau
astrogliopathy (ARTAG) [16]. Astroglial tau pathology is
common in this aged cohort, most commonly TSA
which, as one of the major constituent subtypes of
ARTAG, are suggested to be an age-related tauopathy
rather than disease-specific. Located particularly in sub-
pial, subependymal and perivascular locations, these
have been described in mesial temporal structures espe-
cially in ageing brains [19, 29]. Recognised best with
AT8-immunohistochemistry, they appear to express 4R-
tau and can be variable detected with antibodies to p62.
Variable staining with Gallyas silver preparations sug-
gests that some of the tau is fibrillary. Tufted astrocytes,
which are a feature of progressive supranuclear palsy,
were identified in 10 % of our cases, suggesting that they
can be seen in ageing brain. However, they were present
as isolated cells, and the morphology of many of these
showed more finely granular processes, suggesting that
they are more akin to the “astrocytes with finely granular
tau immunoreactivity in processes” which have been de-
scribed in mesial temporal structures in the elderly [15, 17].
We now show that these isolated forms of astrocyte tau
pathology are not confined to mesial temporal structures in
the ageing brain, whilst their significant association with
TSA supports the concept that are part of the constellation
of age-related astroglial tauopathy.
We demonstrated that the frequency of TSA increases
with ageing in this cohort of older people, among whom
more that 75 % were 85 years and over at death. There
was, however, only a positive trend with age when par-
ticipants with dementia and without were considered to-
gether, and this had a low odds ratio. Other studies
suggest that they are uncommon in younger brains, not
included in our study [29]. Thus, whilst age may be an
important influence on their pathogenesis, as for neur-
onal tau, ageing is only a marginal effect within an
already aged-population. A fuller study of the relation-
ship to age will require a cohort with a wider ageing
spectrum.
Whilst TSA are particularly prevalent in mesial tem-
poral areas, we further show that they develop around
the brainstem, which is an important site in the early de-
velopment of AD pathology [33], and less frequently in
neocortical areas. Although not formally assessed in this
study, they are also very common in a subpial location
beneath the substantia innominata and in the semilunar
and ambient gyri. Thus they are particular prevalent at
basal surfaces of the brain. These are also areas with
early NT and NFT formation. Our previous study, re-
stricted to the mesial temporal area, did not demonstrate
a relationship between TSA and Braak NFT stage [19].
However, this study, which takes account of three brain
areas, does demonstrate weak correlation of TSA with
both BNE NT stage and Braak NFT stage, suggesting
that TSA formation may be loosely associated with
neuronally-derived tau pathology.
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TSA were significantly associated with tau in subpial
neurites, right at the brain surface. These, along with
subependymal tau, are in neurites in close proximity to
CSF. Indeed some tau appears to be present within
ependyma. The cellular location of this staining remains
to be determined, but neuronal processes are described
that contact ventricular CSF [35]. It could be hypothe-
sised that this represents a disposal pathway for aggre-
gated tau. The presence of corpora amylacea in this
zone might also support this as a disposal route. An al-
ternative possibility is that tau at this location might rep-
resent an early site of induction in response to CSF
factors (Personal Communication, Udo Rub, Frankfurt,
Germany). In either case, the presence of tau at this lo-
cation is very common and may be important in the
pathogenesis of age and AD-associated tau. Astrocytes
have been previously shown to take up Aβ-aggregates,
contributing to plaque progression and moving these ag-
gregates towards the pial surface. The association of
TSA with subpial neuritic tau raises the possibility that
they result from astrocytic uptake of aggregated tau
along this disposal pathway. However, in situ induction
of tau in astrocytes still needs to be formally excluded.
There are a number of limitations to this study. CFAS
is a population-based study. This has advantages for this
type of analysis, where an unbiased approach is ideal,
but it also imposes limitations compared to clinicopath-
ologically defined case–control cohorts, to which the
population-based approach is complementary (reviewed
in [32]). For example, dementia in CFAS is defined by a
dichotomizing, algorithmic approach. This approach is
reliable compared to clinical assessment, is ideal for
population studies, and has provided high quality epi-
demiological data on dementia. [13, 21, 36]. It does,
however, lack the more textured approach of detailed
neuropsychological assessment that can be employed in
well-defined clinic-derived populations, thereby limiting
assessment of the relationship of grading schemes to
specific aspects of cognitive impairment in CFAS.
The areas chosen were primarily to assess the BNE
NT stage, as defined by the BNE protocol, but this may
constitute limited sampling for comprehensive assess-
ment of prevalence of tau cytopathologies, including
astroglial tau. This is particularly relevant for TSA,
which can be focal and which are also seen in subpial
basal forebrain areas not assessed in this sampling
protocol. Thus TSA prevalence may be underestimated.
Semi-quantification of TSA in this study was also limited
to presence in one, two or three areas. Assessment of
further areas and more quantitative approaches may
produce a more graded scaling, allowing more powerful
exploration of relationships. Sampling guidelines cur-
rently being suggested are likely to have a valuable im-
pact here [16]. Whilst this is a sizeable cohort, the low
odds ratios in some analyses (especially for TSA), sug-
gest that larger numbers may better establish some rela-
tionships. Furthermore, the CFAS cohort is an aged
cohort; assessment in cohorts with a wider age spectrum
are required to better elucidate broader ageing relation-
ships. Lastly, although the AT8 antibody is widely used
in research and diagnosis, this is a tau prevalence study
based on a single antibody recognising a specific tau
modification.
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